<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230529058327N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-08-03</date_registration>
      <primary_sponsor>Bu Ali Sina University</primary_sponsor>
      <public_title>Effect of two high intensity interval training and one moderate continuous training methods on apo B/apo A ratio and ABCA1, ABCG1 expression in CABG patients.</public_title>
      <acronym></acronym>
      <scientific_title>Effect of two high intensity interval training and one moderate continuous training methods on apo B/apo A ratio and ABCA1, ABCG1 expression in CABG patients.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/70415</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Simple randomization
The names of 40 CABG patients who referred to the heart hospital for the second stage of rehabilitation after the operation were written on paper and each person was randomly assigned to one of the four control groups, MIT, HIIT20 and HIIT60, Blinding description: The patient was explained the exercise program, the duration of the exercise, and how to do the activity. Also, the rehabilitation doctor, physiotherapist, nurse and psychologist were aware of the type and method of exercise, but they did not know what exercise method could have a specific effect.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Coronary artery bypass grafting.</hc_freetext>
      <i_freetext>Intervention 1: Control group: They did not receive any special training. Intervention 2: Intervention group 1: moderate-intensity continuous training (MIT). They received continuous aerobic exercises of 60%-80% maximum aerobic powe for three sessions a week with three devices: 1. Treadmill 2. Hand ergometer 3. Foot ergometer. Intervention 3: Intervention group 2: high-intensity interval training (HIIT20 sec). Intervention 4: Intervention group 3: high-intensity interval training (HIIT60 sec).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
TC,ABCA1, ABCG1,apoA,apoB, HDL, LDL,TG

When:
2023

To whom:
researchers

Conditions:
The average data of the groups is available.

Where to obtain:
Ali heidarianpour:   Heidarian317@gmail.com
Ali Reza Ahmadvand:  Alireza.led@gmail.com

How to obtain:
About a month

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>AliReza Ahmadvand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mahdieh Ave., Jafari Street.</address>
        <city>Hamedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6517733968</zip>
        <telephone>+98 81 3825 4825</telephone>
        <email>alireza.led@gmail.com</email>
        <affiliation>The University of Bu Ali Sina</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ali Heidarianpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shariati Street, Pajohesh Square, Hamedan, Iran.</address>
        <city>Hamedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>65178-38695</zip>
        <telephone>+98 81 3838 1422</telephone>
        <email>Heidarian317@gmail.com</email>
        <affiliation>Bu Ali Sina University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Coronary artery bypass grafting patient
male
At least two months have passed since their surgery.</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>65 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Met less than 5
Injection fraction less than 30
blood pressure
Arthritis</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I25.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Atherosclerotic heart disease of native coronary artery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: They did not receive any special training.</i_keyword>
      <i_keyword>Intervention group 1: moderate-intensity continuous training (MIT). They received continuous aerobic exercises of 60%-80% maximum aerobic powe for three sessions a week with three devices: 1. Treadmill 2. Hand ergometer 3. Foot ergometer.</i_keyword>
      <i_keyword>Intervention group 2: high-intensity interval training (HIIT20 sec).</i_keyword>
      <i_keyword>Intervention group 3: high-intensity interval training (HIIT60 sec)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>ATP-binding cassette transporter A1 (ABCA1). Timepoint: before the start of the first training session and 48 hours after the last training session (Week 8). Method of measurement: Blood sampling from patients.</prim_outcome>
      <prim_outcome>ATP-binding cassette transporter B1 (ABCG1). Timepoint: before the start of the first training session and 48 hours after the last training session (Week 8). Method of measurement: Blood sampling from patients.</prim_outcome>
      <prim_outcome>Apolipoprotein A-1 (apoA-1). Timepoint: before the start of the first training session and 48 hours after the last training session (Week 8). Method of measurement: Blood sampling from patients.</prim_outcome>
      <prim_outcome>High-density lipoprotein (HDL). Timepoint: before the start of the first training session and 48 hours after the last training session (Week 8). Method of measurement: Blood sampling from patients.</prim_outcome>
      <prim_outcome>Apolipoprotein B (apoB-1). Timepoint: before the start of the first training session and 48 hours after the last training session (Week 8). Method of measurement: Blood sampling from patients.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Bu Ali Sina University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-02-28</approval_date>
        <contact_name>Ethics Committee of Bu Ali Sina University</contact_name>
        <contact_address>Mahdieh Hamedan Hamadan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
